Drugs /

umbilical cord blood-derived natural killer cells

Back to Drugs List

Overview

NCI Definition [1]:
A population of allogeneic, cytokine-differentiated, highly lytic natural killer (NK) cells derived from CD34+ cells isolated from human umbilical cord blood (UCB) with potential cytotoxic activity. CD34+ hematopoietic stem cells (HSC) are isolated from human UCB mononuclear cells, differentiated into mature, highly lytic, CD3- CD56+ NK cells, by a specific combination of cytokines that includes stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (Flt3-L), interleukin-15 (IL-15) and insulin-like growth factor-1 (IGF-1), and expanded ex vivo. Upon administration, the UCB-derived NK cells may lyse cancer cells.

Clinical Trials

View Clinical Trials for umbilical cord blood-derived natural killer cells

Umbilical cord blood-derived natural killer cells has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating umbilical cord blood-derived natural killer cells, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

EMC-92 High Risk Multiple Myeloma, Hypodiploidy, and IGH-FGFR3 Fusion are the most frequent biomarker inclusion criteria for umbilical cord blood-derived natural killer cells clinical trials.

Anaplastic large cell lymphoma, B-cell non-hodgkin lymphoma, and hodgkin lymphoma are the most common diseases being investigated in umbilical cord blood-derived natural killer cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Umbilical Cord Blood-Derived Natural Killer Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating umbilical cord blood-derived natural killer cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cord blood nk cells, umbilical cord blood-derived nk cells, cord blood nk cells, umbilical cord blood-derived nk cells
NCIT ID [1]:
C118949

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.